Research Nester released a report titled “Ocular Tuberculosis Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global ocular tuberculosis therapeutics market in terms of market segmentation by treatment, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Ocular tuberculosis is a form of tuberculosis in which the TB bacteria infects various parts of an eye. The disease can be spread easily from one person to another, making it highly infectious and thus raising the demand for efficient therapeutic drugs.
The market for ocular TB therapeutics market is anticipated to expand with a significant CAGR during the forecast period, i.e., 2019-2027. The growth can be attributed to increasing demand for improved and highly effective therapeutics for ocular tuberculosis. Moreover, the rising prevalence of tuberculosis across various regions in the world is another factor that is estimated to increase the demand for ocular TB therapeutics.
On the basis of treatment, the market is segmented into first line treatment, second line treatment and combination therapy, out of which, the combination therapy segment is estimated to observe highest growth rate during the forecast period. This can be attributed to the increasing evolution of multidrug resistant tuberculosis bacteria, which possesses the ability to resist the effect of tuberculosis therapeutics. This generates the demand for combination therapy which uses various combinations of drugs that are more effective than monotherapy (single drug treatment).
North America is anticipated to hold the largest market share in ocular TB therapeutics market during the forecast period on account of growing advancements in the healthcare industry in the region. The increasing demand for improved therapeutics for tuberculosis is another factor estimated to drive the growth of market. However, the market in Asia-Pacific region is anticipated to grow at the highest rate during the forecast period. Increasing incidences of tuberculosis and growing healthcare infrastructure in the region are some of the notable factors that are responsible for the market expansion.
Growing Prevalence Of Ocular TB To Boost The Market Growth
W.H.O. reported that around 10 million people were infected by tuberculosis in 2017 and 1.6 million deaths as a result of the disease were reported. The disease is prevalent in countries with large population including China, India and the U.S. Increasing cases of ocular tuberculosis in these countries is a major growth driver supporting the growth of the ocular tuberculosis therapeutics market.
However, rare occurrence of ocular tuberculosis and incomplete research studies conducted on the disease resulting in a limit availability of therapeutics might act as a major barrier to the growth of the market during the forecast period.
This report also provides the existing competitive scenario of some of the key players of the global ocular tuberculosis therapeutics market which includes company profiling of Bayer AG (BAYN), BioVersys, Concept Pharmaceuticals Ltd., Labatec-Pharma SA, Macleods Pharmaceuticals Ltd., Johnson & Johnson (JNJ), Pfizer (PFE), Sandoz International, Sanofi (SAN) and Sequella Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global ocular tuberculosis therapeutics market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.